Proton Pump Inhibitor (PPI)Not Controlled

Prilosec®

Omeprazole

AstraZeneca/Generic·FDA September 1989·
10mg20mg40mgOTC: 20mg

Version 2025-04 · Last reviewed April 1, 2025 · Methodology

List Price

$20–40 (OTC brand)

With Insurance

$5–15

How It Works

Omeprazole permanently inactivates the proton pump — the molecular machine that secretes acid into the stomach. New pumps must be synthesized to restore acid production, which is why a drug with a 1-hour half-life can suppress acid for 72+ hours.

Irreversibly inhibitsH+/K+-ATPase (proton pump)
Permanently inactivates acid-secreting pumps in stomach's parietal cells — acid secretion stops until new pumps are made (24–72 hours)

Why the side effects happen

The stomach acid suppressed by PPIs serves important functions: digesting protein, absorbing vitamins B12 and magnesium, and preventing bacterial overgrowth. Long-term suppression leads to B12 deficiency, magnesium depletion, increased C. difficile risk, and small intestinal bacterial overgrowth (SIBO). "Rebound hyperacidity" on stopping occurs because the parietal cells have upregulated their pump count in response to chronic suppression — a key reason PPIs are hard to stop.

When Will I Feel It?

Some acid reduction on day 1. Meaningful heartburn relief by day 3–5. Full GERD healing takes 4–8 weeks of consistent daily use.

1
Day 1–2First days

Some acid reduction but not full suppression — new drug works on existing pumps; full effect requires existing pumps to cycle over.

2
Day 3–5Days 3–5

Meaningful heartburn relief. Take 30 minutes before the first meal for best effect — the drug needs an active pump to bind.

3
Week 4–84–8 weeks

Full esophageal healing for erosive GERD. This is the minimum course for GERD with esophageal damage.

4
StoppingAfter stopping

Rebound hyperacidity in many patients — acid secretion surges above baseline for 2–8 weeks. This drives patients to restart.

Adherence Note

Take on an empty stomach 30–60 minutes before your first meal of the day — this is when proton pumps are most active and the drug works best. Taking with food dramatically reduces efficacy. Do not crush delayed-release capsules.

Medical Disclaimer

The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.

Common Side Effects

While taking this medication, you may experience the following common side effects. We've included tips on how to manage them.

Headache

7%

Usually resolves; if persistent, consider switching to an H2 blocker

Nausea / diarrhea

4%

Take before first meal; usually self-resolving within days

Magnesium deficiency (long-term)

22%

Annual magnesium blood test for users >1 year; supplement if needed

Vitamin B12 deficiency (long-term)

18%

Annual B12 test for users >2 years; supplement sublingually

C. difficile infection risk

1.7× increased

Avoid PPIs during and after antibiotics if possible; use probiotics

Rebound acid on stopping

40%+

Step down gradually rather than stopping abruptly; dietary changes help ease transition

Serious Adverse Effects

  • Chronic kidney disease — long-term PPI use independently associated with CKD progression
  • Increased risk of dementia — observational data; monitor annually if >5 years of use
  • Bone fracture risk — PPIs reduce calcium absorption; annual bone density for long-term users >50
  • Hypomagnesemia (severe) — can cause seizures and cardiac arrhythmias if undetected

Drug Interactions

Major Interactions (Avoid)

Clopidogrel (Plavix)PPIs reduce clopidogrel antiplatelet effect by 40–50% via CYP2C19 inhibition — increases cardiovascular event risk in patients on dual antiplatelet therapy.
MethotrexatePPIs reduce renal clearance of methotrexate, increasing toxicity risk — particularly in oncology patients.

Moderate Interactions (Caution)

Atazanavir / Rilpivirine (HIV antiretrovirals)Requires acidic environment for absorption; PPIs dramatically reduce efficacy of these drugs.
WarfarinMay increase INR; monitor closely when starting or stopping PPIs.
DigoxinPPIs increase digoxin levels by ~10%; monitor in elderly patients.
Iron supplementsGastric acid required for iron absorption; PPIs reduce iron bioavailability significantly.
Vitamin B12 (long-term)Long-term PPI use reduces B12 absorption from food by >60%.
Magnesium depletionChronic use depletes magnesium; monitor levels annually in long-term users.

Food Interactions

AlcoholIrritates stomach lining and worsens GERD — the underlying condition PPIs treat.
Coffee / acidic foodsPrimary dietary triggers of reflux; reducing these may eliminate need for PPIs.

When to Contact Your Doctor

This medication requires ongoing medical supervision. The following situations warrant a prompt conversation with your prescribing physician — do not wait for your next scheduled appointment.

Contact soon if you notice

  • Chronic kidney disease — long-term PPI use independently associated with CKD progression
  • Increased risk of dementia — observational data; monitor annually if >5 years of use
  • Bone fracture risk — PPIs reduce calcium absorption; annual bone density for long-term users >50
  • Hypomagnesemia (severe) — can cause seizures and cardiac arrhythmias if undetected
  • Difficulty swallowing (dysphagia)

Also discuss if you want to

  • Review whether this medication is still appropriate for you
  • Consider dosage adjustments based on response
  • Explore lifestyle or non-drug alternatives
  • Understand stopping or tapering options
  • Plan monitoring labs and follow-up

In the US, call 911 or go to the nearest emergency room for severe symptoms. Poison Control: 1-800-222-1222.

Special Populations

Safety classifications for specific groups — discuss with your provider before use.

Category CPregnancy

Use only if benefit outweighs risk; limited human data.

Use CautionBreastfeeding

Excreted in breast milk; consider alternatives for mild symptoms.

GI Changes After MenopauseMenopause / Hormonal

Estrogen and progesterone affect how well the valve between the esophagus and stomach closes. After menopause, changes in this valve and GI motility can worsen acid reflux. Dietary changes, weight management, and sleep positioning often help significantly before reaching for a daily PPI.

Approved 1+ year for GERDChildren & Teens

Use for shortest duration possible; pediatric GERD often resolves with dietary modification.

Use CautionOlder Adults

Higher risk of C. diff, fractures, B12 deficiency, and kidney disease. Reassess need every 6 months.

Monitor AnnuallyKidney Disease

Long-term PPI use independently associated with CKD progression; monitor eGFR annually.

Reduce DoseLiver Disease

Hepatic impairment reduces omeprazole clearance; max 20mg/day in severe cases.

FDA Adverse Event Reports

Patient-filed reports from the FDA FAERS database · refreshed daily

Anecdotal data. Reports are not confirmed causation. Always consult your provider.

Community Reports

User-reported experiences — anonymous & anecdotal

Medical Disclaimer

The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.

Metabolic & Lifestyle Alternatives

🥗 Dietary Changes Resolve Acid Reflux in 60–80% of Patients

A 2-week elimination diet resolves symptoms in most GERD patients — PPIs treat the symptom while the cause continues

Important context: Evidence quality varies across these approaches. Some are well-studied with randomized controlled trial data; others are based on observational or smaller studies. These interventions are not guaranteed to replace medication for all patients. Discuss with your doctor whether any of these are appropriate for your clinical situation.

Global Prescribing & Pricing

PPIs are among the most overprescribed drug classes globally — US patients stay on them 5–10× longer than guidelines recommend

🇺🇸

United States

$10–20 (generic OTC)/mo

Rate

Most patients prescribed indefinitely despite 4–8 week indication; 15% of US adults use PPIs

Policy

OTC availability means many patients self-prescribe indefinitely with no medical review

Cover

OTC available; prescription covered by most plans

🇬🇧

United Kingdom

~$2–5 (NHS)/mo

Rate

Comparable prescribing volume but step-down mandated

Policy

NICE requires step-down from PPI to H2 blocker or on-demand use after 4–8 weeks; lifestyle counseling mandatory

Cover

Fully covered by NHS

🇫🇷

France

~$3–8/mo

Rate

Lower chronic use — stricter reassessment requirements

Policy

HAS guidelines mandate reassessment at 4 weeks; lifestyle modification counseling documented at each renewal

Cover

Covered by Sécurité Sociale

🇩🇪

Germany

~$5–12/mo

Rate

Step-down therapy standard practice

Policy

S3 guidelines require documented step-down attempt and lifestyle counseling before continuing beyond 8 weeks

Cover

Covered by GKV

🇯🇵

Japan

~$8–18/mo

Rate

Lower GERD prevalence due to diet; PPIs used more acutely

Policy

H. pylori eradication is emphasized (very high H. pylori prevalence); dietary counseling integrated into GI care

Cover

Covered by JHIS

Germany's S3 guidelines require documented step-down therapy before extending PPI beyond 8 weeks. The UK's NICE mandates switching to on-demand use after the acute episode resolves. The US has no equivalent standard — producing a generation of permanent PPI users who were started on them for a 4–8 week condition.

Clinical Trials & Funding

Understanding who funds research helps contextualize results. Industry-funded trials are not automatically invalid — they undergo the same FDA review — but declared conflicts and sponsor effects are worth knowing. All linked trials can be verified on ClinicalTrials.gov.

Funding Sources

Original approval trials funded by AstraZeneca and Astra AB. Pivotal studies were designed for 4–8 week acute use. Long-term safety data came primarily from post-marketing studies — often after millions had been using PPIs for years. AstraZeneca later developed esomeprazole (Nexium), the mirror-image molecule, to maintain patent exclusivity — widely cited as a classic "evergreening" strategy.

Declared Conflicts of Interest

AstraZeneca funded key efficacy trials and shaped early prescribing guidelines. Independent long-term studies (kidney disease, dementia, B12 deficiency) were published 10–20 years after widespread adoption. The chronic kidney disease association (PMID: 26174986) and dementia signal (PMID: 26864376) were not discovered until PPIs were already among the most prescribed drugs globally.

Key Efficacy Results

80–90% short-term acid suppression efficacy; intended for 4–8 weeks; most patients end up on indefinitely with no reassessment

Referenced Studies

Each study carries a Cochrane RoB-2 risk-of-bias badge — tap the badge for details.

Evidence & Transparency

Cochrane RoB-2 (Risk of Bias)

Badges reflect an editorial assessment using Cochrane's RoB-2 tool domains: randomization, intervention deviation, missing data, outcome measurement, and selective reporting. These are not certified Cochrane reviews. Learn more ↗

CMS Open Payments

Manufacturer payment disclosures are reported via the CMS Sunshine Act. Disclosure is legally required and does not imply bias or misconduct. Language uses "may," "suggests," or "appears" — never definitive clinical claims. CMS Open Payments ↗

Live Clinical Trials

Live from ClinicalTrials.gov · refreshed every 4 hours

Currently enrolling, active, and recently completed studies involving Omeprazole. Data is pulled directly from the U.S. National Library of Medicine.

Recent Research

Live from PubMed · peer-reviewed literature · refreshed every 4 hours

Most recently indexed clinical trials and systematic reviews mentioning Omeprazole in PubMed.

Source Documentation

Structured citations for referenced clinical trials

Each referenced trial is listed with its registry ID, funding source, and bias assessment. Use the copy button to generate a formatted citation.

TrialRegistry IDCite
Omeprazole vs H2 Blockers (ASTRONAUT)PMID:9062047
PPI & Chronic Kidney DiseasePMID:26174986
PPI & Dementia Risk (JAMA)PMID:26864376

Bias ratings use Cochrane RoB-2 methodology. Editorial assessment — not a certified Cochrane review.

Our Methodology

Medical Disclaimer

The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.

Stopping This Medication Safely

Taper to Avoid ReboundDocumented timeframe: 4–8 weeks with step-down

Abruptly stopping PPIs causes rebound acid hypersecretion — the stomach overproduces acid for 2–4 weeks, often causing symptoms worse than the original GERD. This leads many patients to restart unnecessarily. A gradual taper prevents this cycle.

What Published Research Shows About Stopping This Medication

This summarizes what published research documents — it is not personal medical advice. Any changes to your medication require discussion with your prescribing physician.

  • ·Research supports stepping down to every-other-day dosing for 2 weeks before stopping completely
  • ·Switching to an H2 blocker (famotidine/Pepcid) for 2–4 weeks as a bridge is a documented clinical approach
  • ·Research supports implementing dietary changes (eliminating triggers) 1–2 weeks before reducing the dose
  • ·Calcium carbonate (Tums) or sodium bicarbonate are documented for breakthrough symptoms during the stopping process
  • ·Research documents rebound acid symptoms in weeks 1–2 — this is a documented pharmacological effect and does not necessarily indicate treatment needs to be restarted

Warning Symptoms — Contact Your Doctor If You Experience:

  • Difficulty swallowing (dysphagia)
  • Black or bloody stools (possible ulcer bleeding)
  • Unexplained weight loss with reflux symptoms
  • Pain radiating to back or severe chest pain

Never change or stop a medication without consulting your prescribing physician.

Questions for Your Doctor

Questions to Ask

  • 1.Do I actually need this long-term, or was it started for a short-term reason?
  • 2.Can we try stepping down to an H2 blocker or on-demand use?
  • 3.Should we test for H. pylori before assuming I need ongoing acid suppression?
  • 4.Am I being monitored for B12, magnesium, and kidney function annually?
  • 5.What dietary changes would you recommend to reduce or eliminate this medication?

Lab Tests to Request

  • H. pylori test (breath or stool antigen)
  • Vitamin B12 level
  • Serum magnesium
  • Kidney function (eGFR) — annually for long-term users
  • Bone density if on PPIs >5 years

Medical Disclaimer

The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.

Frequently Asked Questions About Prilosec®

What is Prilosec® used for?
Prilosec® (Omeprazole) is a Proton Pump Inhibitor (PPI) manufactured by AstraZeneca/Generic. FDA-approved indications include: GERD / acid reflux; Peptic ulcer disease; H. pylori eradication (combination); Zollinger-Ellison syndrome; NSAID-induced ulcer prevention.
What are the common side effects of Prilosec®?
Common side effects of Prilosec® include: Headache (7%); Nausea / diarrhea (4%); Magnesium deficiency (long-term) (22%); Vitamin B12 deficiency (long-term) (18%); C. difficile infection risk (1.7× increased).
How much does Prilosec® cost?
Prilosec® list price is approximately $20–40 (OTC brand). With insurance it typically costs $5–15; without insurance approximately $10–20 (OTC generic).
Who funded the clinical trials for Prilosec®?
Original approval trials funded by AstraZeneca and Astra AB. Pivotal studies were designed for 4–8 week acute use. Long-term safety data came primarily from post-marketing studies — often after millions had been using PPIs for years. AstraZeneca later developed esomeprazole (Nexium), the mirror-image molecule, to maintain patent exclusivity — widely cited as a classic "evergreening" strategy.
How strong is the clinical evidence for Prilosec®?
Key studies: ASTRONAUT trial (1997), OMNIUM trial (1998), Nordic PPI study, multiple long-term observational studies on harms. 80–90% short-term acid suppression efficacy; intended for 4–8 weeks; most patients end up on indefinitely with no reassessment Potential conflicts of interest: AstraZeneca funded key efficacy trials and shaped early prescribing guidelines. Independent long-term studies (kidney disease, dementia, B12 deficiency) were published 10–20 years after widespread ado.
Are there non-drug alternatives to Prilosec®?
A 2-week elimination diet resolves symptoms in most GERD patients — PPIs treat the symptom while the cause continues See the Alternatives tab for full details.

Get notified when we update Prilosec®

We'll email you when new evidence, safety updates, or alternatives are added.

No spam. Unsubscribe anytime.